title: Reactogenecity of indigenously produced measles vaccine.
abstract: OBJECTIVE
  To assess the safety and reactogenecity of indigenously produced measles vaccine derived from EZ strain.
  
  
  METHODS
  A longitudinal clinical follow up after vaccination.
  
  
  METHODS
  Hospital based and home follow up, as required.
  
  
  METHODS
  12,470 children, 9 to 15 months old, immunized with measles vaccine of EZ strain, in accordance with the National Immunization Schedule, at five centers.
  
  
  METHODS
  A clinical follow up of children at 1 day, 1 week, 2 weeks, 3 weeks and 6 weeks after measles vaccination. A detailed clinical neurological examination in children showing side effects.
  
  
  RESULTS
  Mild side effects were documented in 31%. Of these, 90% were seen in the first two weeks, out of which two thirds were seen during the first week. Commonest side effects were coryza (10%), fever (9.8%), cough (3.2%) and diarrhea (3.2%). Convulsions, with no later sequelae were documented in 2 cases only.
  
  
  CONCLUSIONS
  Measles vaccine manufactured in India, using EZ strain is a safe vaccine. It has a level of reactogenecity including neurological aspects, lower than that reported in India with the Schwarz strain vaccine.
authors.affiliation: Serum Institute of India Research Foundation, Pune.
authors.forename: I
authors.initials: I
authors.lastname: Bhargava
authors.forename: B C
authors.initials: BC
authors.lastname: Chhaparwal
authors.forename: M A
authors.initials: MA
authors.lastname: Phadke
authors.forename: S F
authors.initials: SF
authors.lastname: Irani
authors.forename: B K
authors.initials: BK
authors.lastname: Chakladhar
authors.forename: C P
authors.initials: CP
authors.lastname: Maheshwari
mesh_terms: D006801:Humans; D007194:India; D007223:Infant; D008137:Longitudinal Studies; D008458:Measles Vaccine / Q000009:adverse effects*
chemical_list: D008458:Measles Vaccine